Compare GSK plc (GSK) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nutrien Ltd — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Nutrien Ltd trades at $67.07 (market cap $32.46B). The key difference: GSK plc is far larger — about 3.1× Nutrien Ltd's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NTR | |
|---|---|---|
Market Cap | $101.34B | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $83.94 |
52-Week Low | $36.20 | $53.64 |
Enterprise Value | $121.95B | $45.62B |
Dividend Yield | 3.49% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Nutrien (NTR) trades at $67.04, down 2.33% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a net income margin of 8.58%. Recent news highlights strong fertilizer demand and cost-cutting efforts, though input cost pressures persist. Cash flow trends indicate consistent operational strength despite negative net cash flow in recent periods.
Outlook remains positive with analyst consensus pointing to a $77.67 price target and 63.64% buy ratings. Key opportunities include robust potash sales and healthy industry demand, while risks involve volatile input costs and margin compression from supply chain challenges. The stock presents a value proposition with a P/E of 13.92 trading below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
